Bristol Myers Squibb paid $380 million to reserve manufacturing capacity on a machine that had never treated a single patient. That is not a milestone announcement. That is a commercial bet, and it tells you everything about the real story behind the first two patients dosed last week with rese-cel, an experimental gene-modified cell therapy for autoimmune disease made on Cellares' automated manufacturing platform. CAR T, a therapy that reprograms a patient's own immune cells to attack disease, has worked in blood cancer for over a decade. The manufacturing cost and complexity have kept it locked in oncology's rarefied economics — until now.
The wire framed this as a clinical milestone: two patients received a CAR T cell therapy produced by Cellares' Cell Shuttle, an automated manufacturing system. That is accurate. It is also the least interesting thing happening here. The interesting thing is that before those two patients were treated, BMS locked up manufacturing space on a system that does not yet have regulatory approval for commercial use. The company is betting that Cellares can solve a problem that has kept cell therapies stuck in oncology's rarified economics: the cost and complexity of making a personalized drug for each patient.
A conventional CAR T manufacturing run requires taking a patient's own immune cells, shipping them to a specialized facility, engineering them over one to two weeks of manual labor, and shipping them back. The list price for approved CAR T therapies in oncology runs from $400,000 to $500,000 per patient. The manufacturing cost is a significant portion of that. For autoimmune diseases like lupus, myositis, or myasthenia gravis — where patient populations are orders of magnitude larger than relapsed lymphoma — those economics do not work at scale. The only path forward is automation.
Cellares claims its Cell Shuttle delivers roughly ten times the throughput of a conventional contract manufacturing facility of similar size, with lower per-patient costs. The platform received FDA Advanced Manufacturing Technology designation, which allows the agency to review the manufacturing process in parallel with clinical data — a regulatory shortcut that signals the agency views the platform as a priority. The company is building what it calls IDMO Smart Factories in South San Francisco, Bridgewater, New Jersey, Leiden in the Netherlands, and Kashiwa in Japan, with the stated goal of producing cell therapies for hundreds of thousands of patients annually.
That is an enormous ambition. The current global CAR T market treats roughly 10,000 patients per year. Cellares' own pitch — backed by $612 million in total raised capital including a $257 million Series D led by BlackRock and Eclipse in January 2026 — is that its automated approach is the only way to close the gap between what cell therapy can do in theory and who can actually access it. BMS's $380 million capacity reservation is the most concrete evidence that a major drugmaker agrees.
Cabaletta Bio, the Philadelphia-based biotech developing rese-cel, is not waiting for the Cell Shuttle's commercial approval to find out. The company announced in March 2026 that it plans to submit a Biologics License Application to the FDA for rese-cel in myositis — a muscle-damaging autoimmune condition — in 2027, based on a single-arm registrational cohort of 17 patients. If approved, rese-cel would be the first CAR T therapy explicitly cleared for autoimmune disease.
The caveat is that none of this has been proven at commercial scale. The Cell Shuttle has treated patients in clinical trials; it has not yet been inspected and approved as a commercial manufacturing site. Cellares' Smart Factory in South San Francisco is under construction. The company's 10-fold throughput claim is based on internal benchmarking against conventional facilities — independent verification does not yet exist. And BMS's $380 million reservation covers capacity, not product: the agreement does not guarantee that BMS will commercialize any therapy made on the platform, only that it will have the right to use the manufacturing space if it chooses to.
What is clear is that the bottleneck in cell therapy has never been the science. CAR T has worked in blood cancer for over a decade. The problem is that making a living cell drug per patient, by hand, in a limited number of facilities, is expensive and slow. If Cellares is right that automation fixes the unit economics, the implications extend well beyond lupus and myositis. Every company with a cell therapy program — and there are dozens in autoimmune alone — will need to answer the same question BMS has already answered internally: build your own manufacturing, or buy access to someone else's.
